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Abstract
Purpose The first two studies aiming for the high-
throughput identification of the somatic mutation spectrum
of colorectal cancer (CRC) tumors were published in 2006
and 2007. Using exome sequencing, they described 69 and
140 candidate cancer genes (CAN genes), respectively. We
hypothesized that germline variants in these genes may
influence CRC risk, similar to APC, which is causing CRC
through germline and somatic mutations.
Methods After excluding the well-established CRC genes
APC, KRAS, TP53, and ABCA1, we analyzed 35 potentially
functional single-nucleotide polymorphisms (SNPs) in 10
CAN genes (OBSCN, MLL3, PKHD1, SYNE1, ERCC6,
FBXW7, EPHB6/TRPV6, ELAC1/SMAD4, EPHA3, and
ADAMTSL3) using KBiosciences Competitive Allele-Spe-
cific PCRTM genotyping assays. In addition to CRC risk
(1,399 CRC cases, 838 controls), we also considered the
influence of the SNPs on patients’ survival (406 cases).
Results In spite of the fact that our in silico analyses
suggested functional relevance for the studied genes and
SNPs, our data did not support a strong influence of the
studied germline variants on CRC risk and survival. The
strongest association with CRC risk and survival was found
for MLL3 (rs6464211, OR 1.50, p = 0.002, dominant
model; HR 2.12, p = 0.020, recessive model). Two SNPs
in EPHB6/TRPV6 (dominant model) showed marginal
associations with survival (rs4987622 HR 0.58 p = 0.028
and rs6947538 HR 0.64, p = 0.036, respectively).
Conclusion Although somatic mutations in the CAN
genes have been related to the development and progres-
sion of various types of cancers in several next-generation
sequencing or expression analyses, our study suggests that
the studied potentially functional germline variants are not
likely to affect CRC risk or survival.
Keywords Colorectal cancer  Risk  Survival  SNP 
CAN genes
Introduction
Cancer research has made great progress through the tech-
nological achievements in molecular genetics. Next-gener-
ation sequencing (NGS) and genome-wide association
studies (GWAS) have offered new insights into the origin,
development, and progression of cancer. Identification of
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new genetically defined tumor subtypes, driver mutations,
and molecular genetic markers may point out new options
for risk assessment and therapeutic targets and help clini-
cians to take informed treatment decisions, making cancer
therapy more effective and less harmful.
Although colorectal cancer (CRC) is among the most
common human cancers and its ‘‘adenoma to carcinoma
sequence’’ is well defined [14, 50], little is known about
predictive and prognostic markers that could guide treatment
decisions with reasonable accuracy. Up to date, only very few
genetic markers (KRAS, BRAF, microsatellite instability) are
included in the European treatment guidelines for CRC [12].
In addition to the prognostic markers, large efforts have been
taken to identify genes that predispose to CRC and may allow
risk estimations for this cancer [48]. However, many stud-
ies—both candidate gene and GWAS approaches—have
shown contradictory results and together still have failed to
explain much of the genetic susceptibility to CRC [11, 20,
48], not least because of the possible influence of environ-
mental risk factors [21, 22]. If it were possible to predict
individual’s CRC risk with adequate accuracy, individuals
with additional personal risk factors, such as obesity, diabe-
tes, or inflammatory bowel disease, could benefit from early
detection screenings or lifestyle interventions [4, 21].
It is known that germline mutations in a number of tumor
suppressor genes, including APC, TP53, and VHL, cause
various cancers, but these genes are also somatically mutated
in sporadic tumors [18]. As NGS data have been generated
from many tumor types over the past years, we posit that in
analogy to the above tumor suppressors, there may also be
cancer-related germline variants in the genes commonly
mutated in sporadic tumors. The first high-throughput exome
sequencing study on CRC tumors was published in 2006 and
described 69 candidate cancer genes (CAN genes) out of a
list of 519 somatic mutations that were found in tumor
samples [39]. In 2007, a second, similar study described a
longer list of 140 CAN genes, confirming most of the pre-
vious findings [55]. Despite the high mutation load of the
tumors, the individual driver mutations were rare somatic
mutations in some relevant genes.
We hypothesized that germline mutations or polymor-
phisms in these genes may have functional or regulatory
effects on CRC susceptibility or prognosis. Thus, we
investigated whether polymorphisms in the CAN genes
may be modifiers of CRC risk or prognosis.
Materials and methods
Study population
The study was carried out on a CRC case–control popu-
lation from the Czech Republic (Supplementary Material,
Table S1). All cases and controls were of Czech ancestry.
Between 09/2004 and 10/2010, 1,399 CRC cases were
recruited by nine oncological departments in the Czech
Republic (58.5 % males) [30]. All patients were diagnosed
with colon or rectal malignancy by colonoscopy (67.1 %
colon). The medical evidence was confirmed histologically
as CRC. Patients who met the Amsterdam criteria I or II for
hereditary nonpolyposis colorectal cancer (HNPCC) [49]
were excluded from the study in order to collect a sample
set of nonsyndromic CRC. The control population con-
sisted of 838 blood donors that were recruited during the
same time period by a blood donor center in one hospital in
Prague, Czech Republic (51 % males). The health status of
the blood donors was verified during a standard health
examination in the course of the blood donation, and the
donors were cancer free at the time of sampling [30].
A subgroup of 406 CRC patients diagnosed between
2003 and 2010 was available for a survival analysis with
comprehensive clinical data at the time of diagnosis.
Beside general information about age, sex, TNM stage
classification (size or direct extent of the primary tumor
[T], degree of spread to regional lymph nodes [N], pre-
sence of metastasis [M]) [41], and grade, information about
distant metastasis, relapse, and date of death was available
with a follow-up until 31 August 2011.
Gene and SNP selection for genotyping
For this study, we selected and genotyped 35 single-
nucleotide polymorphisms (SNPs) to test their associations
with CRC risk or prognosis (Fig. 1 and Supplementary
Material Table S2). The SNPs were located in genes that
showed somatic mutations in at least four of the 35 CRC
tumor samples ([10 % of tumors) analyzed by Sjöblom
et al. [39] and Wood et al. [55]. The well-known and
extensively studied CRC genes, APC, KRAS, TP53, and
ABCA1, were not considered as candidates for our study.
Ten somatically mutated genes (OBSCN, MLL3,
PKHD1, SYNE1, ERCC6, FBXW7, EPHB6/TRPV6,
ELAC1/SMAD4, EPHA3, ADAMTSL3) were analyzed for
potentially functional nonsynonymous SNPs (nsSNPs),
using the search terms ‘‘nonsense,’’ ‘‘missense,’’ ‘‘frame-
shift,’’ and ‘‘stop gained,’’ listed in NCBI dbSNP 136 [10]
and validated by HapMap (Supplementary Material, Table
S2) [45, 46]. All these functional SNPs were considered
promising candidates for the association study. We ana-
lyzed the relevant gene regions for the linkage disequilib-
rium (LD) in order to prevent parallel analysis of highly
linked polymorphisms (r2 C 0.85) (Haploview: V2. R24.
Analyse Panel CEU) [2]. This approach further allowed us
to select only those SNPs for genotyping that are located in
DNA sequences acceptable for the design of the genotyp-
ing assays. In case of nonacceptable flanking sequence of
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the SNP of interest, we selected a highly linked SNP
(r2 C 0.85) located in an acceptable DNA sequence as a
tagging SNP.
We analyzed the polymorphisms for allele frequency
differences (AFDs) among the HapMap populations (YRI
vs. CEU, CHB, and JPT). The AFD was used as an ‘‘easy
to access’’ value that may indicate selective processes in
genes and SNPs and point to hidden functionality beyond
coding/noncoding categories [31]. Additional methods
were used to confirm these signatures of selection in all
Fig. 1 Workflow of the stepwise approach of candidate gene and SNP selection and of the downstream analysis of the data. *Exception of the
MAF cut off: MLL3 MAF [ 1 %; **the list of functional SNPs and candidate SNPs is shown in Supplementary Table S2
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genes and SNPs that were found to be associated with CRC
risk or patients’ survival (cf. paragraph ‘‘Functional Pre-
diction and Signatures of Selection’’ below). With the
exception of MLL3 that mostly harbored SNPs with very
low allele frequency (\0.05), only SNPs with a minor
allele frequency (MAF) [10 % were considered for
genotyping.
Genotyping
The DNA used in this study was obtained from peripheral
blood lymphocytes taken from the study participants at the
collaborating hospitals. All DNA extracts underwent whole
genome amplification before genotyping (illustra Genom-
iPhi V2 DNA Amplification Kit GE HealthcareTM). For
genotyping, ‘‘KBiosciences Competitive Allele-Specific
PCR’’ (KASPTM) system was used. PCR reactions were
carried out in a 384 well format using 3 ng of whole
genome amplified DNA per reaction in a 4 ll reaction
volume. The PCR conditions for the individual assays were
set according to the recommendations by KBiosciences.
Endpoint genotype detection was carried out on an ABI
PRISM 7900-HT Sequence Detection System with SDS 2.2
software (Applied Biosystems). As an internal quality
control, 7 % of the samples were randomly selected as
duplicates. The concordance rate between the original and
the duplicate samples was C99 %. The average call rate
was 94.7 % (89.5–97.1 %). Thirty samples were excluded
from the study due to bad overall performance [\50 % of
all 35 genotypes called (B17 genotypes)].
Statistical analysis
The observed genotype frequencies in the controls were
tested for Hardy–Weinberg equilibrium (HWE) using
Pearson’s goodness-of-fit v2 tests. Deviation from HWE
was assumed at p \ 0.01. Odds ratios (ORs) and 95 %
confidence intervals (CIs) for associations between geno-
types and CRC risk were estimated by logistic regression
(PROC LOGISTIC, SAS Version 9.2; SAS Institute, Cary,
NC). The estimated effects for all SNPs refer to the minor
allele. p values \0.05 were considered statistically signif-
icant. To account for the differences in the age and sex
distributions between the cases and the controls (mean age
62 vs. 45.6 years p \ 0.0001; 58.5 vs. 51.0 % males
p = 0.005), the ORs were adjusted for age and gender. For
all SNPs with significant p values per genotype, the best
model (dominant or recessive) was calculated. For poly-
morphisms with MAF [ 10 %, we had [90 % power to
detect an OR of 1.5 at a significance level of 0.05, using the
dominant model (Quanto V1.2.4) [34]. Differences in the
survival between patients carrying different genotypes
were estimated by hazard ratios (HRs) and 95 % CIs
(PROC PHREG, SAS Version 9.2, SAS Institute, Cary,
NC) using Cox regression. For all SNPs with significant
p values per genotype (p value\0.05), the best model was
calculated (dominant or recessive model) and they were
analyzed further adjusting the data separately for age,
gender, T, N and M status, and grade. Additionally, Kap-
lan–Meier plots were generated for these SNPs, and the
differences between the survival functions among the
groups were estimated by the log-rank test (PROC LIF-
ETEST, SAS Version 9.2; SAS Institute, Cary, NC).
Functional prediction and signatures of selection
Functional polymorphisms may exert an increased likeli-
hood of having a pronounced effect on a disease [47].
Signatures of selection are suggested to indicate function-
ality beyond coding/noncoding categories [31] and to
provide a value for the functional relevance of a SNP. The
SIFT [26, 38] and PolyPhen-2 [1, 33] browsers were used
to predict functional consequences of the nsSNPs. SNP-
nexus [40] and HaploReg v2 [19, 52] were used to predict
regulatory consequences of the analyzed SNPs and any
linked SNP (r2 [ 0.85). The fixation index (FST) and AFD
values were used to assess the degree of population dif-
ferentiation among the HapMap populations, indicating
selective processes [8, 56]. FST values [0.25 indicate
strong genetic differentiation, while values in the range
between 0.05 and 0.1 indicate moderate genetic differen-
tiation [8, 56]. Fay Wu’s H was used to detect signatures of
selection via the estimation of local changes in the fre-
quency spectrum of the SNPs within the candidate genes
[13]. The integrated haplotype score (iHS) is defined by the
local LD in a gene or a gene region, and it was used to
detect signatures of selection in the haplotype structure of
the candidate genes [35, 51]. Strong negative Fay-Wu’s H
values were considered as signatures for a selective sweep,
and iHSs\-2 or[2 give evidence for a powerful selection
signal [13, 42, 51]. These four estimates together provide
sufficient evidence if a locus has been under natural
selection and shed light on its functional relevance [7, 31].
Results
Case–control study
For one SNP out of the 35 tested (rs765525 in PKHD1), a
significant deviation from HWE was detected. This SNP
was excluded from the analysis. For the majority of tested
SNPs, the observed genotype frequencies did not differ
significantly between the case and the control groups
(Supplementary Material, Table S3). However, an associ-
ation with CRC risk was detected for three SNPs in a
762 Cancer Causes Control (2014) 25:759–769
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dominant model, adjusted for age and sex (Table 1):
rs6464211 in MLL3 (OR 1.50, 95 % CI 1.16–1.93,
p = 0.002), rs10252263 in MLL3 (OR 2.41, 95 % CI
1.08–5.37, p = 0.03), and rs4253038 in ERCC6 (OR 0.71,
95 % CI 0.55–0.93, p 0.01). The associations did not
remain significant after adjustment for multiple testing
using a highly conservative Bonferroni correction (p 0.05/
35 = 0.0014).
Survival analysis
For three polymorphisms, significant differences in the
survival between the carriers of the minor allele and the
carriers of the major allele were detected either in the
dominant or recessive model (p value \0.05).
According to the recessive model, homozygous carriers
of the minor allele in rs6464211 (MLL3: HR 2.12, 95 % CI
1.12–4.01, p = 0.02, Table 2) showed decreased survival
rates compared to the carriers of the major allele. In con-
trast, carriers of the minor allele in rs4987622 and
rs6947538 in EPHB6/TRPV6 showed increased survival
rates compared to the homozygous carriers of the major
allele [(HR 0.58, 95 % CI 0.36–0.94, p = 0.03, Table 2)
and (HR 0.64, 95 % CI 0.42–0.97, p = 0.04, Supplemen-
tary Material, Table S4), respectively]. These two SNPs
were in LD in the Czech control population (r2 = 0.68)
and supported the results of each other. Kaplan–Meier plots
were generated for these three polymorphisms (Fig. 2,
from the EPHB6/TRPV6 SNPs, only rs4987622 is shown).
All three analyzed polymorphisms showed significant dif-
ferences in the survival function (log-rank p value B0.05).
The associations did not remain significant after adjustment
for multiple testing using Bonferroni correction (p 0.05/
35 = 0.0014).
Functional prediction and selective pressure
The three SNPs associated with CRC risk or patients’
survival are coding synonymous (rs6464211 in MLL3) and
intronic (rs4987622 and rs6947538 in EPHB6/TRPV6)
polymorphisms, respectively, for which no regulatory
consequences were predicted by SNPnexus. However,
HaploReg v2 predicted effects on regulatory motives for all
three SNPs and several linked variants (r2 [ 0.85). The
SNP rs6464211 in MLL3 and four linked SNPs (r2 [ 0.85)
may affect 42 regulatory motives. For the two SNPs in
EPHB6/TRPV6, the prediction resulted in two not over-
lapping lists of 40 SNPs highly linked to rs4987622
(r2 [ 0.9) and of 33 SNPs highly linked to rs6947538
(r2 [ 0.8) that may affect 126 and 78 regulatory motives,
respectively.
Signatures of selective pressure were analyzed as an
indicator of functionality such as regulatory function of a
locus or genetic hitchhiking due to a highly selected
unknown functional variant [3, 7, 13, 31]. For all three
SNPs, several signatures of selection were detected
(Table 3). We found signatures of strong population dif-
ferentiation between CEU and YRI indicated by AFD
(rs6464211 0.7, rs4987622 0.57, and rs6947538 0.64,
respectively), FST values (0.49, 0.40, and 0.47, respec-
tively), and significant changes in the frequency spectrum
of genetic variants around the tested SNPs (Fay Wu’s H
values: -129.6, -47.24, and -43.78, respectively;
Table 3). We did not find significantly elevated |iHS|
values.
Discussion
The 10 genes tested in the present study were mutated in
10–19 % of the tumor samples analyzed by Sjöblom et al.
[39] and Wood et al. [55]. Only the already well-studied
genes APC, KRAS, and TP53 were mutated more fre-
quently. According to our data, the studied germline vari-
ants do not have a strong influence on CRC risk and
survival.
Among the 35 studied SNPs, we found marginal effects
on CRC risk or patients’ survival for three different genes.
Table 1 CRC risk in relation to MLL3 rs10252263, MLL3
rs6464211, and ERCC6 rs4253038
Risk of CRC—adjusted for age and sex




C/T 16 41 2.407 [1.08–5.37] 0.03*
T/T – – – – –




C/T 198 408 1.545 [1.18–2.02] 0.001**
T/T 26 34 1.137 [0.59–2.19] 0.70




C/T 340 570 0.736 [0.56–0.97] 0.03*
C/C 154 212 0.663 [0.47–0.94] 0.02*
C/T ? C/C 494 782 0.713 [0.55–0.93] 0.01*
Associations between genotypes and CRC risk were considered sig-
nificant at p \ 0.05; level of significance * \0.05; ** \0.005
OR odds ratio, CI confidence interval
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Table 2 Overall survival in relation to MLL3 rs6464211 and EPHB6/TRPV6 rs4987622




C/C 242 134 (55.4) 0.044a*
C/T 135 69 (51.1) 0.90 [0.67–1.20] 0.455
T/T 13 10 (76.9) 2.04 [1.07–3.89] 0.030*
Recessive model (CC ? CT vs. TT) 2.12 [1.12–4.01] 0.020* 0.017*
Adjusted for age
C/C 242 134 (55.4)
C/T 135 69 (51.1) 0.90 [0.67–1.21] 0.483
T/T 13 10 (76.9) 2.11 [1.10–4.02] 0.024*
Recessive model (CC ? CT vs. TT) 2.19 [1.15–4.14] 0.016*
Adjusted for sex
C/C 242 134 (55.4)
C/T 135 69 (51.1) 0.90 [0.67–1.20] 0.479
T/T 13 10 (76.9) 1.98 [1.04–3.77] 0.038*
Recessive model (CC ? CT vs. TT) 2.05 [1.09–3.88] 0.027*
Adjusted for tumor size (T)
C/C 228 123 (53.9)
C/T 119 57 (47.9) 0.90 [0.66–1.23] 0.502
T/T 11 8 (72.7) 2.07 [1.01–4.25] 0.048*
Recessive model (CC ? CT vs. TT) 2.15 [1.05–4.37] 0.036*
Adjusted for degree lymph node involvement (N)
C/C 212 110 (51.9)
C/T 110 55 (50.0) 0.95 [0.68–1.31] 0.736
T/T 9 6 (66.7) 2.23 [0.97–5.13] 0.059
Recessive model (CC ? CT vs. TT) 2.27 [1.00–5.19] 0.051
Adjusted for presence of distant metastasis (M)
C/C 232 128 (55.2)
C/T 129 67 (51.9) 0.87 [0.65–1.17] 0.357
T/T 13 10 (76.9) 1.79 [0.94–3.43] 0.077
Recessive model (CC ? CT vs. TT) 1.89 [1.00–3.58] 0.052
Adjusted for the grade of the cancer cells
C/C 206 112 (54.4)
C/T 113 56 (49.6) 0.87 [0.63–1.20] 0.389
T/T 9 6 (66.7) 1.57 [0.69–3.58] 0.283
Recessive model (CC ? CT vs. TT) 1.65 [0.73–3.74] 0.229
EPHB6/TRPV6
rs4987622
T/T 321 185 (57.6) 0.069a
C/T 45 18 (40.0) 0.60 [0.37–0.97] 0.038*
C/C 1 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.58 [0.36–0.94] 0.028* 0.025*
Adjusted for age
T/T 321 185 (57.6)
C/T 45 18 (40.0) 0.59 [0.37–0.96] 0.034*
C/C 1 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.57 [0.35–0.93] 0.025*
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The strongest association with CRC risk and survival was
found for the MLL3 gene. Furthermore, we found that
polymorphisms in EPHB6/TRPV6 may be associated with
survival. Common SNPs in these three genes have not
previously been described to be associated with risk or
survival of CRC [9, 36]. The location of the SNPs geno-
typed in each of the three genes in relation to the mutations
found in CRC tumors is shown in Fig. 3 [39, 55]. Strong
signatures of natural selection detected in MLL3 and
EPHB6/TRPV6 and the predicted effects on regulatory
motifs support the hypothesis that the variants in these
genes may play a functional role for the genes and related
pathways [3, 7, 13, 31].
As a component of a histone modification complex
histone 3-lysine 4 (H3K4), MLL3 plays an important role in
epigenetic regulation of gene transcription. Furthermore, it
has been described to be involved in p53-dependent DNA
damage response as being part of the H3K4
methyltransferase coactivator complex of p53 [17, 27]. In
this function, MLL3 was suggested as a tumor suppressor.
In NGS and whole genome studies, mostly published in the
year 2012, MLL3 has been found to be mutated in CRC and
several other types of cancers [15, 39, 55]. Strikingly,
MLL3 was frequently found in microsatellite instable CRC,
with nonfunctional DNA repair mechanisms [5, 25, 28, 37,
53]. In our study, we found one SNP in MLL3 to be mar-
ginally associated with CRC risk and survival in micro-
satellite stable CRC. The genomic location of MLL3 on
chromosome 7q36.1 is within a region with very high
recombination rates; however, MLL3 only harbors 13 SNPs
with a MAF [ 0.05 (Haploview V2, R24 CEU). In con-
trast, there are 54 SNPs with a MAF between 0.01 and
0.05, which tightly link MLL3 to the neighboring gene
GALNT11 (Supplementary Material, Figure S1). GALNT11
is involved in the mucin-type O-glycosylation, a pathway
that has been related to CRC especially via MUC1 and
Table 2 continued
At risk Died (%) HR 95 % CI p value Log-rank
p value
Adjusted for sex
T/T 321 185 (57.6)
C/T 45 18 (40.0) 0.58 [0.36–0.95] 0.029*
C/C 1 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.56 [0.35–0.91] 0.020*
Adjusted for tumor size (T)
T/T 291 162 (55.7)
C/T 43 16 (37.2) 0.60 [0.36–1.00] 0.048*
C/C 1 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.59 [0.35–0.98] 0.042*
Adjusted for degree lymph node involvement (N)
T/T 271 148 (54.6)
C/T 38 14 (36.8) 0.66 [0.38–1.14] 0.135
C/C 0 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.66 [0.38–1.14] 0.135
Adjusted for presence of distant metastasis (M)
T/T 307 178 (58.0)
C/T 43 17 (39.5) 0.66 [0.40–1.08] 0.097
C/C 1 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.60 [0.36–0.98] 0.042*
Adjusted for the grade of the cancer cells
T/T 267 149 (55.8)
C/T 40 17 (42.5) 0.67 [0.41–1.11] 0.117
C/C 1 0 (0.0) – – –
Dominant model (TT vs. CT ? CC) 0.65 [0.39–1.07] 0.091
Genotypes with individual adjustments for age, sex, T, N, M, and grade
HR hazard ratio, CI confidence interval
Associations between genotypes and survival were assumed significant at p B 0.05; level of significance * \0.05, ** \0.005
a Overall log-rank p value for the survival distribution function per genotype
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Fig. 2 Kaplan–Meier plots for
the survival distribution
function of the SNPs in
a EPHB6/TRPV6 and b MLL3
(best model)
Table 3 Signatures of selection in the SNPs significantly associated with CRC risk and/or overall survival
Gene SNP Functiona Association Signatures of selection AFD (%) FST Fay Wu’s H iHS
Risk of CRC Survival
EPHB6/TRPV6 rs4987622 Intronic variant No association HR 0.58, p = 0.028;
log-rank p = 0.025
(dominant model)
56.6 0.4 -47.24 -1.22
EPHB6/TRPV6 rs6947538 Intronic variant No association HR 0.64, p = 0.036;
log-rank p = 0.034
(dominant model)
64.2 0.47 -43.78 -1.58
MLL3 rs6464211 Synonymous variant OR 1.50, p = 0.002
(dominant model)
HR 2.12, p = 0.020;
log-rank p = 0.017
(recessive model)
70.1 0.49 -129.61 -0.18
AFD allele frequency difference YRI versus CEU, estimation based on the minor allele in CEU, updated with dbSNP137, Jan 2013, validation
status HapMap CEU, FST fixation index, iHS integrated haplotype score
a dbSNP137 (Jan 2013)
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MUC2 [6, 24]. Rs6464211 is characterized by a strong
signal of natural selection with highly significant values for
the fixation index (FST) and Fay Wu’s H estimates [13, 16,
31, 43].
EPHB6 belongs to the Eph-family receptor tyrosine
kinases and is expressed in almost every human tissue [29].
It is located at 7q33-q35 in close proximity to another gene:
TRPV6. TRPV6 belongs to the superfamily of cation
channel proteins and is frequently expressed in placenta,
pancreas, prostate, and CRC cell lines, with lower
expression in kidney and small intestine [32]. In our study,
we analyzed two SNPs within a high LD block linking the
two genes EPHB6 and TRPV6 with an r2 C 0.76 (Haplo-
view V2. R24. CEU) and an r2 = 0.68 in the Czech control
population (Supplementary Material, Figure S2). Our data
suggest that either rs4987622 in TRPV6 or rs6947538 in
EPHB6 may be associated with survival. Because of the
LD between the two genes, it is not clear whether the
detected effect can be attributed to one of the two geno-
typed variants in EPHB6 or TRPV6 or any other linked
variant in this particular region. However, Sjöblom et al.
and Wood et al. addressed EPHB6 as the actual CAN gene.
The estimates analyzed for signatures of natural selection
are very similar for both SNPs and point to a selective
process that has shaped the gene region. HaploReg v2
predicted effects on regulatory motives for both SNPs and
several linked variants (r2 [ 0.85). Additionally, both
genes, EPHB6 and TRPV6, have been found mutated and
differentially expressed in various tumor types such as
breast, lung, and gastric cancer (COSMIC Release v63)
[15].
Our study has both strengths and limitations. Strengths
include its candidate gene study design, using a well-
defined and genetically homogeneous study population
with a sufficient size. From the altogether 1,399 cases, only
the 406 consecutively collected incident cases diagnosed in
2003 or later were available for the survival analysis. This
ensured that only newly diagnosed CRC cases (within one
year of diagnosis before enrollment for this study) were
included to the study, excluding a survival bias. For this
subgroup, nearly complete clinical data were available,
allowing evaluation of the SNPs as independent prognostic
markers. However, the limitation to newly diagnosed CRC
cases made some subgroup analyses small and decreased
the power to detect associations with genotypes. Another
limitation of the study may be that only a few SNPs were
studied in each gene. Based on our hypothesis that germ-
line variants in the genes commonly mutated in sporadic
CRC may influence CRC risk or survival, the study
intentionally focused on potentially functional coding
SNPs. Therefore, other SNPs in or nearby the selected
genes that may contribute to the risk or survival of CRC
might have been missed.
In conclusion, our study did not provide evidence of a
strong association of the 35 studied potentially functional
SNPs with CRC risk or survival. However, an effect of
Fig. 3 Location of the genotyped SNPs within EPHB6/TRPV6 and
MLL3. Plot of the genomic position of the genotyped SNPs in relation
to the somatic mutations and in relation to common nsSNPs within
the four genes described in Sjöblom et al. [11]. *SNPs found to be
significantly associated with CRC risk and/or survival; plots adapted
from http://bio.ieo.eu/fancygene/. Red lines indicate nonsynonymous
SNPs, and green lines indicate synonymous SNPs. (Color figure
online)
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other germline variants within frequently mutated CAN
genes cannot be excluded. A retrospective analysis of the
latest publications (effective January 2014) about the
mutational landscape of CRC conclusively lists three of our
candidate genes among the most commonly mutated and
important genes in CRC: SYNE1, FBXW7, and SMAD4 [23,
44]. Also, MLL3 and EPHB6/TRPV6 have been repeatedly
found mutated in CRC tumor samples, although with
varying mutation frequencies [44]. Further and larger
studies on frequently mutated CAN genes will be necessary
in the future to understand their functional role on CRC
risk, progression, and prognosis.
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